Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
2017
Sorafenibis a promising agent for treating pediatric
refractoryacute myeloid leukemia (AML) exhibiting FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD); however, its optimal use needs to be established. We report 2 cases of
refractorypediatric FLT3-ITD-positive AML treated with
sorafenib. Case 1 underwent stem cell transplantation (SCT) without entering remission, despite the use of chemotherapy. This patient relapsed despite receiving post-SCT
sorafenib. Chemotherapy combined with
sorafenibsuccessfully achieved complete remission in case 2. This patient received post-SCT
sorafeniband remains in complete remission. The combination of pre-SCT and post-SCT
sorafenibmay thus be effective for pediatric
refractoryFLT3-ITD-positive AML.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
14
References
1
Citations
NaN
KQI